Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
We are grateful for Ling Fang from Instrumental Analysis & Research Center of Sun Yat-sen University for technical support
Comparison of key peptide properties: GHK-Cu Half-life: approx
Summary: Retatrutide FDA Status Retatrutide is not FDA-approved and won't be for at least another year It's in Phase 3 trials (TRIUMPH program) with results expected in late 2026 FDA approval is projected for 20272028 Phase 2 data showed 24.2% weight loss , better than any approved GLP-1 medication Current access: clinical trials (free), compounded retatrutide ($200$500/mo), or research peptides ($150$500/mo) When approved, retatrutide will be the first triple-agonist obesity medication on the market References Jastreboff AM, Aronne LJ, Ahmad NN, et al
Dont waste your money on the compounded orals (compounded injectables, on the other hand, have been very effective in my experience)
Research-grade retatrutide occupies the next tier
This is why users notice clearer skin, less acne, and reduced inflammation
US$ 22.58
US$ 26.53
US$ 22.38
US$ 25.48
